You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
麗珠醫藥(01513.HK)預計2019年淨利約12.45億元-13.53億元 同比增約15%-25%
格隆匯 01-09 18:25

格隆匯1月9日丨麗珠醫藥(01513.HK)公告,公司公佈2019年度業績預告。2019年度歸屬於上市公司股東的淨利潤約人民幣12.45億元—13.53億元,比上年同期增長約15%-25%;歸屬於上市公司股東的扣除非經常性損益的淨利潤約人民幣11.37億元-12.31億元,比上年同期增長約20%—30%;基本每股收益約人民幣1.33元/股—1.45元/股。

公司2019年度經營業績與上年同期相比同向上升的主要原因是:公司不斷深化營銷體制改革,實行精細化管理,化學制劑業務板塊盈利增長較上年明顯加快;由於高端特色原料藥業務的快速增長以及工藝提升帶來的成本下降,原料藥業務板塊盈利大幅增長。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account